<DOC>
	<DOCNO>NCT00627445</DOCNO>
	<brief_summary>This trial conduct Asia . The trial aim investigate blood glucose control biphasic insulin aspart 50 least effective treatment biphasic insulin aspart 30 combination metformin .</brief_summary>
	<brief_title>Effect Biphasic Insulin Aspart 50 Blood Glucose Control Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes Currently treat premix human insulin twice daily without oral antidiabetic drug least 3 month HbA1c ( Glycosylated Haemoglobin A1c ) 7.5 % 12.0 % ( inclusive ) FPG ( Fasting Plasma Glucose ) high 7.0 mmol/L BMI ( Body Mass Index ) 2340 kg/sq.m ( inclusive ) Metformin contraindication accord local practice Systemic use TZDs ( thiazolidinediones ) 1 month within 6 month prior trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>